Parabilis Medicines, Inc. (PBLS) Stock Statistics & Valuation Metrics

Parabilis Medicines, Inc. has a market cap or net worth of $4.75B. The enterprise value is $2.31K.

Parabilis Medicines, Inc. has 121,952,030 shares outstanding. The number of shares has decreased by -2.65% in one year.

Parabilis Medicines, Inc.’s return on equity (ROE) is 8.83 and return on invested capital (ROIC) is -338.57%.

The current PE Ratio of Parabilis Medicines, Inc. is ―. Parabilis Medicines, Inc.’s PEG ratio is -0.02.

In the last 12 months, Parabilis Medicines, Inc. had revenue of 0.00 and earned -145.89M in profits. Earnings per share was -92.40.

In the last 12 months, operating cash flow was -52.82M and capital expenditures -985.00K, giving a free cash flow of -53.81M billion.

Parabilis Medicines, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Parabilis Medicines, Inc. upcoming earnings date is Aug 13, 2026, Before Open (Confirmed).

Parabilis Medicines, Inc. as a current ratio of 0.52, with Debt / Equity ratio of 4.53%

In the past 12 months, Parabilis Medicines, Inc. has paid 0.00 in taxes.

Parabilis Medicines, Inc. EV to EBITDA ratio is -0.50, with an EV/FCF ratio of -0.58.

Parabilis Medicines, Inc. has $1.12B in cash and marketable securities with $47.51M in debt, giving a net cash position of $1.07B billion.

Gross margin is 100.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Parabilis Medicines, Inc. is $40.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy